Back To Search Results

Clin Asst Prof Tan Wan Ling

MBBS, MRCK (UK), MMed (Internal Med), FAMS (Medical Oncology)

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Clinical Interest: Head ＆ Neck, Thoracic-Oncology, Uro-Oncology, Lung, Nasopharynx

Conditions Treated by this Doctor:
Bladder Cancer, Head and Neck Cancer, Kidney Cancer, Larynx Cancer, Lung Cancer, Nasopharyngeal Cancer (Nose Cancer), Oral Cancer, Prostate Cancer, Thyroid Cancer.

Clinical Appointments

Senior Consultant NCCS Oncology @ SKH Sengkang General Hospital
Senior Consultant Division of Medical Oncology National Cancer Centre Singapore

Academic Appointments

Clinical Assistant Prof at Duke-NUS Medical School

Profile

Dr Tan Wan Ling is a Senior Consultant in Medical Oncology at the National Cancer Centre Singapore and Clinical Assistant Professor at DUKE-NUS Medical School. She obtained her undergraduate medical degree from the National University of Singapore in 2008 and her membership from the Royal College of Physicians of the United Kingdom in 2012. She completed her 3-year Senior Residency training in Medical Oncology in 2016 and her clinical and research interests are in thoracic and head & neck oncology.

Education

M. Med (Internal Med), National University of Singapore, 2012
MRCK (UK), Royal College of Physicians (UK), 2012
MBBS, National University of Singapore, 2008

Professional Appointments and Committee Memberships

Senior Consultant, Department of Medical Oncology, National Cancer Centre Singapore
Fellow of Academy of Medicine, Singapore (FAMS)
Singapore Society of Oncology (SSO), Member
European Society for Medical Oncology (ESMO), Member
International Association for the Study of Lung Cancer (IASLC)

Awards

SingHealth and NCCS 10 Years Long Service Award, 2020
Singapore Health Quality Service Awards (Silver), 2019
Outstanding Faculty RiSE Award (Singhealth Residency), 2018
IASLC Academy Award, 2017
20th CSCO Annual Meeting Travel Award, 2017
Outstanding Resident RiSE Award (Singhealth Residency), 2014
The SingHealth Best Medical Officer Award, 2013
The SingHealth Best Medical Officer Award, 2012

Research Interests

Publications

Tan AC, Seet AOL, Lai GGY, Lim TH, Lim AST, Tan GS, Takano A, Tai DWM, Tan TJY, Lam JYC, Ng MCH, Tan WL, Ang MK, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim WT, Tan EH, Lim TKH, Tan DSW. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. J Thorac Oncol. 2020 Dec;15(12):1928-1934. doi: 10.1016/j.jtho.2020.08.011. Epub 2020 Aug 28. PMID: 32866654
Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. J Thorac Oncol. 2020 Mar;15(3):324-343. doi: 10.1016/j.jtho.2019.10.022. Epub 2019 Nov 13.PMID: 31733357
Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim AST, Lim WT, Toh CK, Tan EH, Lim TKH, Tan DSW. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer. 2020 Jan;139:207-215. doi: 10.1016/j.lungcan.2019.11.022. Epub 2019 Nov 26.PMID: 31835042
Dijksterhuis WPM, Stroes CI, Tan WL, Ithimakin S, Calles A, van Oijen MGH, Verhoeven RHA, Barriuso J, Oosting SF, Ivankovic DK, Furness AJS, Bozovic-Spasojevic I, Gomez-Roca C, van Laarhoven HWM. From presentation to paper: Gender disparities in oncological research. Int J Cancer. 2019 Aug 31.
GGY Lai, TH Lim, J Lim, PJR Liew, XL Kwang, R Nahar, ZW Aung, A Takano, YY Lee, DPX Lau, GS Tan, SH Tan, WL Tan, MK Ang, CK Toh, BS Tan, A Devanand, CW Too, A Gogna, BH Ong, TPT Koh, R Kanesvaran, QS Ng, A Jain, T Rajasekaran, J Yuan, TKH Lim, AST Lim, AM Hillmer, WT Lim, NG Iyer, WL Tam, W Zhai, EH Tan, DSW Tan. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer. J Clin Oncol. 2019 Apr 10;37(11):876-884. doi: 10.1200/JCO.18.00177
Tan WL, Ng QS, Lim C, Tan EH, Toh CK, Ang MK, Kanesvaran R, Jain A, Tan DSW, Lim DW. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. BMC Cancer. 2018 Dec 3;18(1):1198. doi: 10.1186/s12885-018-5110-2.
Tan, Wan Ling, & Daniel S. W. Tan. Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer. Translational Lung Cancer Research, Vol 7, Supplement 1 (February 2018). doi: 10.21037/tlcr.2017.11.12
Tan WL, Tan EH, Lim DW, Ng QS, Tan DS, Jain A, Ang MK. Advances in systemic treatment for nasopharyngeal carcinoma. Chinese clinical oncology. 2016 Mar 22;5(2). doi:10.21037/cco.2016.03.03.
Tan WL, Ng Q-S. The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung. Translational Lung Cancer Research. 2016;5(1):106-109. doi:10.3978/j.issn.2218-6751.2015.10.12.
Tan WL, Amit Jain, Angela Takano, Evan W. Newell, N. Gopalakrishna Iyer, Darren Lim, Tan EH, WW Zhai, Axel M. Hillmer, Wai Leong Tam, Daniel SW Tan. Novel Therapeutic Targets on the Horizon for Lung Cancer. Lancet Oncol. 2016 Aug;17(8):e347-62. doi: 10.1016/S1470-2045(16)30123-1.
Choo SP, Tan WL, Brian Goh, David Tai, Andrew Zhu. Comparison of Hepatocellular Carcinoma in Eastern versus Western Populations. Cancer. 2016 Sep 13. doi: 10.1002/cncr.30237.
Sutiman N, Tan SW, Tan EH, Lim WT, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Chowbay B. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. J Thorac Oncol. 2016 Nov 28. pii: S1556-0864(16)33533-X. doi: 10.1016/j.jtho.2016.11.2225.
Marvalim C, Wong JX, Sutiman N, Lim WT, Tan SW, Kanesvaran R, Ng QS, Jain A, Ang MK, Tan WL, Toh CK, Tan EH, Chowbay B. et al. Influence of KDM4A rs586339 polymorphism on overall survival in Asian non-small cell lung cancer patients. Pharmacogenetics and Genomics 2017 Mar;27(3):120-123. doi: 10.1097/FPC.0000000000000266

Research Trials

Tags: Medical Oncology, Head ＆ Neck, Thoracic-Oncology, Uro-Oncology, Lung, Nasopharynx, Bladder Cancer, Head and Neck Cancer, Kidney Cancer, Larynx Cancer, Lung Cancer, Nasopharyngeal Cancer (Nose Cancer), Oral Cancer, Prostate Cancer, Thyroid Cancer